Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
5.630
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine Mindmed Inc
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
May 25, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Calls FDA Experts To Validate LSD Drug Development Strategy
May 25, 2023
In a new chapter of the management quarrel between MindMed (NASDAQ: MNMD) executives and shareholder group FCM Holdings, t
Via
Benzinga
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
May 25, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
Mind Medicine: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Earnings Outlook For Mind Medicine
May 03, 2023
Via
Benzinga
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
May 24, 2023
From
MindMed
Via
Business Wire
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
May 23, 2023
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...
Via
Benzinga
MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
May 19, 2023
MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed.
Via
Benzinga
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
May 17, 2023
From
MindMed
Via
Business Wire
FCM Holdings Accuse MindMed Braintrust Of 'Pursuing Misguided Clinical Path for MM-120'
May 16, 2023
Mind Medicine (NASDAQ: MNMD) activist shareholders FCM MM Holdings are at it again.
Via
Benzinga
FCM Director Nominees Will Put MindMed Drug Development Process Back on Track
May 15, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
May 08, 2023
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
Via
Benzinga
MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections
May 05, 2023
Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business...
Via
Benzinga
FCM Releases Letter to Fellow MindMed Shareholders Highlighting Board and Management’s Track Record of Shareholder Value Destruction
May 05, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
May 04, 2023
From
MindMed
Via
Business Wire
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
May 02, 2023
From
MindMed
Via
Business Wire
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
May 01, 2023
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued
Via
Benzinga
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
May 01, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
3 High-Growth Penny Stocks to Consider Buying in April 2023
May 01, 2023
Here are three high-growth penny stocks long-term investors may want to keep on their watch list, or buy, in April.
Via
InvestorPlace
April Psychedelic Drug Stocks Recap: The Ups And Downs
April 30, 2023
Via
Talk Markets
MindMed CEO On Latest Positive Topline Phase 2 Data And Freedom Capital Management
April 26, 2023
In this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviewed the CEO of Mind Medicine Inc. (NASDAQ: MNMD), Robert Barrow.
Via
Benzinga
MindMed to Participate in May Investor Conferences
April 26, 2023
From
MindMed
Via
Business Wire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...
Via
Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
April 21, 2023
Via
Benzinga
FCM Nominates Exceptional Director Candidates to Restore MindMed’s Value
April 21, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
April 20, 2023
Via
Benzinga
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
April 19, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
April 18, 2023
Via
Benzinga
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
April 18, 2023
From
MindMed
Via
Business Wire
Psychedelic Stock Gainers And Losers From April 17, 2023
April 17, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.